ArticleMaedica2016
New Insights into Antisynthetase Syndrome.
Article in Maedica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Risk Factors for Recurrence of the Anti-Synthetase Syndrome Related Interstitial Lung Disease.Immunity, inflammation and disease · 2026Article
- A case of anti-EJ anti-synthetase syndrome (EJ-ASS) with anti-Ro-52 overlap presenting with progressive interstitial lung disease (ILD) with subtle myopathy - A case report and literature review.Clinical rheumatology · 2025Review
- Article
- Anifrolumab in Refractory Dermatomyositis and Antisynthetase Syndrome.Case reports in rheumatology · 2025Article
- Hidden in Plain Sight: Antisynthetase Syndrome Masquerading As Acute Coronary Syndrome and Heart Failure.Cureus · 2024Article
- A Review of Myositis-Associated Interstitial Lung Disease.Journal of clinical medicine · 2024Review
- From Suspected COVID-19 to Anti-synthetase Syndrome: A Diagnostic Challenge in the Pandemic Era.Cureus · 2024Article
- Autoimmune Dysphagia Related to Rheumatologic Disorders: A Focused Review on Diagnosis and Treatment.Cureus · 2023Review
- Anti-synthetase Syndrome: A Diagnostic Dilemma.Cureus · 2023Article
- IVIG for refractory dysphagia in Antisynthetase syndrome: A truth hard to swallow.Clinical case reports · 2022Article
- Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study.Archives of rheumatology · 2022Article
- A 25-Year-Old Saudi Woman with a 2-Year History of Antisynthetase Syndrome with Interstitial Lung Disease Who Commenced Azathioprine Treatment in the Third Trimester of Pregnancy and Had a Successful Birth at Term.The American journal of case reports · 2022Article
- Myositis-specific Antibodies: Overview and Clinical Utilization.Rheumatology and immunology research · 2022Review
- A multidisciplinary approach to the diagnosis of antisynthetase syndrome.Frontiers in medicine · 2022Review
- Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond.Frontiers in immunology · 2022Review
- A narrative review of interstitial lung disease in anti-synthetase syndrome: a clinical approach.Journal of thoracic disease · 2021Review
- The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitis.Orphanet journal of rare diseases · 2021Article
- Article
- Life-threatening respiratory failure requiring extra-corporeal membrane oxygenation secondary to the anti-synthetase syndrome.Journal of the Intensive Care Society · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antisynthetase syndrome (ASS) is a rare chronic autoimmune disorder (2-3 times more common in women than in men), associated with interstitial lung disease (the most important feature), dermatomyositis (DM), and polymyositis (PM). The cause of ASS is unknown. Recent developments in immunology have improved our knowledge and it is now possible to classify ASS according to the presence of myositis specific autoantibodies. The hallmark of ASS is the presence of serum autoantibodies directed against aminoacyl-tRNA synthetases (anti-ARS involved in protein synthesis). ASS is due to IgG antibodies directed against the enzyme synthase. Antisynthetase antibodies (ASAb) include: anti-histidyl- (anti-Jo-1, being the best known), anti-threonyl- (anti-PL-7), anti-alanyl (anti-PL-12), anti-isoleucyl- (anti-OJ), anti-glycyl- (anti-EJ), anti-asparaginyl- (anti-KS), anti-Wa, anti-tyrosil- (anti-YRS), anti-phenylalanyl-transfer RNA synthetase (anti-Zo), and anti-signal recognition particle (anti-SRP). Anti-Jo-1 is the most common ASAb (in ~20-30% of PM/DM patients).
Identifiers
28461832PMC5394574W2955330547What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.